Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Surgical Wound Infection 4Colorectal Neoplasms 4Rectal Neoplasms 2Pancreatic Neoplasms 2Pancreatic Fistula 1Intestinal Neoplasms 1Exanthema 1Duodenal Neoplasms 1Diarrhea 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Anti-Bacterial Agents × Gastrointestinal × Clear all
NCT03631173 2026-04-28

MINIMUM

Oslo University Hospital

Phase NA Active not recruiting
201 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Duodenal Neoplasms, Pancreatic Fistula, Pancreatic Neoplasms

NCT05462496 2024-10-15

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡